Current and future concepts in stroke prevention

Fintan O’Rourke, Naeem Dean, Naveed Akhtar, Ashfaq Shuaib

Abstract

STROKE IS A MAJOR CAUSE OF MORBIDITY and mortality in an aging population. The current understanding of the pathophysiology of atherosclerotic diseases, the most common cause of stroke, and the evidence for existing therapeutic interventions for the prevention of stroke are presented. Specifically, we review the evidence for antiplatelet agents, anticoagulants, antihypertensive medications, lipid-lowering agents and carotid endarterectomy for stroke prevention.

CMAJ 2004;170(7):1123-33

Each year in Canada stroke occurs in 50 000 people and accounts for 7% of all deaths. Canada’s population of stroke survivors numbers almost 300 000, of whom 30% remain permanently disabled. Care for stroke patients accounts for 2.1% of Canadian health care expenditures. Primary prevention of a first stroke and secondary prevention of recurrent events require rapid identification of risk factors and implementation of appropriate preventive measures.

The risk of stroke following an initial cerebrovascular event is high. Of patients presenting to an emergency department with a transient ischemic attack (TIA), 10.5% will have a stroke (half of these occurring in the first 2 days) and 2.6% will die within 90 days. Overall, 8.8% of stroke survivors will have a recurrent stroke within the first 6 months, and 15% within 5 years. In most cases (about 50%) the stroke is atherothrombotic in origin, with a further 25% attributable to small-vessel lacunar disease and 20% to cardioembolism. Data from a stroke registry reveal that patients who have an atherothrombotic stroke have the highest rates of recurrence within 30 days (18.5%), as compared with those who have a lacunar (1.4%) or cardioembolic (5.3%) stroke.

In this review we present the current understanding of the pathophysiology of atherosclerotic disease, the most common cause of stroke. We also provide an overview of the available evidence for common therapeutic interventions used for stroke prevention: antiplatelet agents, anticoagulants, antihypertensive medications, lipid-lowering agents and carotid endarterectomy.

Atherogenesis

Atherosclerotic plaques begin to appear in the second and third decade of life. It is now widely agreed that inflammation at an endothelial level is the trigger for atherosclerosis. Leukocytes (predominantly monocytes and T-lymphocytes) localize in the earliest atherosclerotic lesions. They bind to vascular cell adhesion molecules (VCAM-1) on the vascular endothelium and migrate into the intima. This initiates and perpetuates a local inflammatory response. The monocytes mature into lipid-scavenging macrophages and subsequently foam cells. T-lymphocytes express inflammatory cytokines, which continue to stimulate macrophages and endothelial cells and further proliferation of smooth muscle cells

Sites that experience disturbed blood flow and increased wall stresses, such as arterial branch points, seem to be at highest risk of atherosclerosis and demonstrate impaired atheroprotective mechanisms. Nitric oxide production, which inhibits platelet aggregation, proliferation of arterial smooth muscle cells and expression of VCAM-1, may be reduced in these sites. Furthermore, smooth muscle cells at these sites produce increased proteoglycans that promote inflammation by facilitating the oxidation of lipoproteins.

Acute rupture of atherosclerotic plaques, rather than gradual encroachment of the plaque causing luminal narrowing, is the main cause of vascular morbidity and mortality. Both immunologic and mechanical forces are thought to be responsible for plaque rupture, which then precipitates thrombosis. Macrophages produce proteolytic enzymes that degrade the collagen of the plaque’s fibrous cap, which makes it susceptible to rupture, and produce procoagulant tissue factor, which triggers plaque thrombosis.

An elevated C-reactive protein level, a marker of inflammation, inhibits nitric oxide release and thus promotes monocyte activation and adhesion to endothelium and increases low-density lipoprotein (LDL) uptake into existing plaques. It is associated with an increased risk of coronary and cerebrovascular events, independent of other known risk factors for vascular disease. Stroke risk in the highest quartile of C-reactive protein levels is almost double among men and threefold among women as compared with the lowest quartile. Therefore, it is hoped that interventions that reduce C-reactive protein levels may also reduce endothelial inflammation and vascular risk. ASA, for example, appears to offer its greatest protective effect in patients in the highest quartile of C-reactive protein levels, reducing the risk of myocardial infarction in this group of men by 55.7% compared with a nonsignificant 13.9% in the lowest quartile of C-reactive protein levels.

Antiplatelet agents

ASA irreversibly blocks platelet cyclooxygenase and thus prevents the formation of thromboxane A₂ (Fig. 2). As a
primary preventive measure, antiplatelet agents do not reduce the risk of ischemic stroke among patients without vascular disease. They are associated with an increased risk of intracranial hemorrhage (odds ratio [OR] 1.35, 95% confidence interval [CI] 0.88–2.10)\(^{23}\) and major noncerebral hemorrhage (OR 1.73, 95% CI 1.14–2.63).\(^{24}\)

The benefits of ASA in the secondary prevention of stroke have been well documented in the period immediately after a stroke\(^{25}\) (Table 1). Long-term antiplatelet treatment after stroke shows an even more impressive reduction of 25 nonfatal strokes and 36 serious vascular events per 1000 treated over a 29-month follow-up period.\(^{25}\) There appears to be no difference in efficacy between low (50 mg) and higher doses (up to 1500 mg) of ASA.\(^ {29,30}\)

The combination of dipyridamole and ASA has been shown to reduce the relative risk of recurrent stroke compared with ASA alone\(^{26}\) (Table 1). Dipyridamole inhibits platelet aggregation by increasing levels of cyclic adenosine monophosphate and cyclic guanosine monophosphate. The limiting factor in the use of the ASA–dipyridamole combination is the latter's potential effects on coronary perfusion. Dipyridamole can cause coronary vasodilation, which results in increased blood flow to nonstenosed coronary arteries. The result is that myocardial ischemia may be provoked during exercise. As such, the current American College of Cardiology/American Heart Association guidelines recommend that dipyridamole not be used in patients with chronic stable angina.\(^ {31}\) However, this recommendation was based on short-acting dipyridamole, which also reduced myocardial ischemia in a similar number of patients in the study quoted by these guidelines.\(^ {32}\) With the use of sustained-release dipyridamole, no increase in cardiac events was observed in subjects with prior coronary artery disease.\(^ {33}\)

Thienopyridines block adenosine-diphosphate–mediated platelet aggregation. Ticlopidine was the first of this class of drug to be studied for stroke prevention. One clinical trial demonstrated that patients treated with ticlopidine had similar rates of stroke as those treated with ASA\(^ {28}\) (Table 1). However, serious granulocytopenia associated with ticlo-
pidine has limited its use. Clopidogrel is a second-generation thienopyridine that has also shown similar efficacy to ASA in stroke prevention27 (Table 1), without any increased risk of major hemorrhage or granulocytopenia. Among patients with acute coronary syndromes, vascular events occurred in 9.3% of those given clopidogrel.

**Fig. 2: Platelet aggregation and subsequent thrombosis may be prevented by several mechanisms and agents.** ASA blocks platelet cyclooxygenase and the formation of thromboxane A$_2$, while the thienopyridines block adenosine-diphosphate–mediated aggregation.

**Table 1: Major trials of antiplatelet agents**

| Trial       | Patients | Follow-up | Intervention | Absolute risk, % | OR (95% CI) | Superior | Comments                                      |
|-------------|----------|-----------|--------------|------------------|-------------|----------|-----------------------------------------------|
| IST/CAST    |          |           | CAST 28 d    | Recurrent IS      |             | ASA      | NNT 7/1000 (CAST); NNT 4/1000                |
| Combined    |          |           | IST 14 d     | Death            |             | ASA v. placebo |                                    |
| analysis$^c$|          |           |              |                  |             | 1.6      | 0.60 (0.51–0.70)                             |
| $n = 40 000$|          |           |              |                  |             | 2.3      | 0.90 (0.80–1.00)                             |
|             |          |           |              |                  |             | 6.1      |                                              |
|             |          |           |              |                  |             | 6.5      |                                              |
| ESPS-2$^a$  | Stroke or TIA | 2 yr       | ASA          | Stroke risk      |             | ASA v. DP | Avoid DP in patients with chronic stable angiina |
| $n = 6602$  | in previous 3 mo |              | v. DP        |                  |             | 12.9     | 0.79 (0.65–0.97)                             |
|             |          |           | v. ASA + DP  |                  |             | 13.2     | 0.81 (0.67–0.99)                             |
|             |          |           | v. placebo   |                  |             | 9.9      | 0.59 (0.48–0.73)                             |
|             |          |           |              | Stroke risk      |             | 15.8     |                                              |
|             |          |           |              | v. placebo      |             | 12.9     |                                              |
|             |          |           |              |                  |             | 13.2     |                                              |
|             |          |           |              |                  |             | 9.9      |                                              |
|             |          |           |              |                  |             | 15.8     |                                              |
| CAPRIE$^b$  | Prior Ml or peripheral arterial disease | 1.91 yr | Clopidogrel   | Composite of IS, Ml, vascular death | 0.91 (0.83–0.96) | Clopidogrel | No difference in efficacy for stroke prevention; no major safety differences |
| $n = 19 185$|          |           | v. ASA       |                  |             | 5.3      |                                              |
|             |          |           |              | Composite of IS, Ml, vascular death | 0.91 (0.83–0.96) | Clopidogrel | No difference in efficacy for stroke prevention; no major safety differences |
|             |          |           |              |                  |             | 5.8      |                                              |
| TASS$^b$    | Minor stroke in previous 3 mo | 2-6 yr | Ticlopidine   | All strokes      | 0.88 (0.61–1.26) | No difference | Ticlopidine rarely used because of safety concerns (2.6% rate of neutropenia in study) |
| $n = 927$   |          |           | v. ASA       |                  |             | 14.2     |                                              |
|             |          |           |              |                  |             | 16.0     |                                              |
|             |          |           |              |                  |             | 20.8     |                                              |
|             |          |           |              |                  |             | 24.8     |                                              |

Note: When not provided in the study, unadjusted odds ratios (ORs) and 95% confidence intervals (CI) were calculated. ASA = acetylsalicylic acid, IS = ischemic stroke, NNT = number needed to treat, TIA = transient ischemic attack, DP = dipyridamole, Ml = myocardial infarction.
O’Rourke et al
grel and ASA, as compared with 11.4% of those given placebo and ASA.\textsuperscript{14} Although there were significantly more patients with major hemorrhage in the clopidogrel group than in the placebo group (3.7% v. 2.7%), there were not significantly more patients with life-threatening or intracranial hemorrhage. To date, there are no published studies specifically examining the ASA–clopidogrel combination in stroke prevention, although several are ongoing.

**Summary**

ASA remains a first-line therapy in the secondary prevention of atherothrombotic stroke after a first episode, although combination therapy with ASA and dipyridamole is also justified in the absence of coronary artery disease. Clopidogrel is recommended if the patient is ASA-intolerant. Patients with recurrent TIA or stroke while taking ASA should be re-evaluated to exclude other pathologies. If none is found, ASA–dipyridamole combination therapy should be given if not already prescribed. Further events, intolerance to dipyridamole or the presence of co-existing coronary or peripheral vascular disease should merit consideration of an ASA–clopidogrel combination therapy.

**Anticoagulants**

Anticoagulation is achieved primarily with heparin and warfarin. Unfractionated heparin binds with antithrombin III and thus accelerates its neutralizing effects on thrombin and inactivates clotting factors. Warfarin, a vitamin K antagonist, prevents the vitamin K-dependent activation of clotting factors II, VII, IX and X.

There is no evidence supporting anticoagulation in the treatment of acute stroke. Although heparin decreases the incidence of recurrent ischemic stroke in the short term, the benefits are offset by increases in the rates of hemorrhagic stroke\textsuperscript{21–17} (Table 2). The remainder of this section examines the role of warfarin in modifying various clinical risk factors for the long-term prevention of stroke.

**Atrial fibrillation**

As previously mentioned, ischemic stroke is due to cardioembolism in about 20% of cases. Of these, the majority occur because of a mural thrombus in patients with atrial fibrillation. The annual rate of stroke with atrial fibrillation is about 4.5%. The risk of stroke is increased among patients who have hypertension, diabetes mellitus, left ventricular dysfunction, prior TIA or stroke and are older than 65. Anticoagulation reduces the annual risk to 1.4%. Patients younger than 65 with atrial fibrillation and no other risk factors had only a 1% rate of stroke, even without treatment.\textsuperscript{46} Long-term treatment with warfarin to achieve an international normalized ratio (INR) above 2.0 decreases not only the risk of stroke, but also its clinical severity and the risk of death.\textsuperscript{46} ASA has also been shown to be more effective than placebo in this group of patients but less effective than warfarin\textsuperscript{46} (Table 2).

The risk of hemorrhagic complications is often a concern when considering long-term anticoagulation for atrial fibrillation. However, one study\textsuperscript{49} demonstrated that the annual risk of ischemic stroke or systemic embolism was greater among patients assigned to low-intensity anticoagulation combined with ASA than among those given full anticoagulation (7.9% v. 1.9%), with no difference in major bleeding (Table 2).

Until recently, conversion of atrial fibrillation to sinus rhythm with the use of electrical or pharmacological methods was felt to be beneficial in reducing long-term embolic complications. However, 2 studies have challenged this concept, showing no significant difference in mortality or stroke reduction between a strategy of restoring and maintaining sinus rhythm and another aimed at rate control of chronic atrial fibrillation. Most strokes occurred only when anticoagulation was stopped or was subtherapeutic.\textsuperscript{44,45}

**Other causes of cardioembolic stroke**

Patients with mechanical prosthetic heart valves are at high risk of stroke from thromboembolism and require anticoagulation at a level determined by the type of valve. If systemic embolism occurs despite adequate anticoagulation with a target INR of 3.0, 80–100 mg of ASA should be added. Patients with bioprosthetic valves require anticoagulation only for the first 3 months after valve insertion. Thereafter, ASA alone is sufficient prophylaxis.\textsuperscript{46}

Despite treatment with thrombolytic agents, left ventricular thrombus may occur in 28% of patients who have an acute anterior myocardial infarction, with even higher rates in the presence of apical hypokinesis.\textsuperscript{47,48} The high risk of subsequent embolic events (OR 5.45, 95% CI 3.02–9.83) may be significantly reduced with anticoagulation (OR 0.14, 95% CI 0.04–0.52)\textsuperscript{49} and has been suggested for 1–3 months after anterior myocardial infarction\textsuperscript{50} especially when complicated by severe left ventricle dysfunction or previous embolii.

The presence of aortic atheroma of 4 mm or more in thickness causes a 3- to 9-fold increased risk of stroke.\textsuperscript{11–31} This risk is further increased if the atheroma is mobile\textsuperscript{31,34} or noncalcified.\textsuperscript{32} The limited evidence available\textsuperscript{52,53} suggests that anticoagulation is superior to antiplatelet treatment in preventing a combined end-point of embolic events and death for atheroma that are 4 mm or more in thickness or are mobile.

The presence of patent foramen ovale (PFO) may increase the risk of ischemic stroke via paradoxical embolism through right-to-left shunting. PFO is found at autopsy in 26% of the general population and 46% of patients with cryptogenic stroke under the age of 55.\textsuperscript{41} A meta-analysis of treatments showed that anticoagulation was superior to antiplatelet therapy for secondary stroke.
prevention in the presence of PFO (OR 0.37, 95% CI 0.23–0.60) and that surgical PFO closure was comparable to anticoagulation (OR 1.19, 95% CI 0.62–2.27). Definitive percutaneous transcatheter closure of PFO has been shown to be successful in preventing neurologic events in previously symptomatic patients, in addition to being safe and minimally invasive. However, a recent study found no difference in 2-year recurrent event rates (stroke or TIA, death) between those with or without PFO and atrial septal aneurysm, which raises the question of

**Table 2: Major trials of anticoagulants**

| Trial    | Patients Follow-up | Intervention                                                                 | Absolute risk | OR (95% CI) | Superior | Comments |
|----------|--------------------|------------------------------------------------------------------------------|---------------|-------------|----------|----------|
| IST      | Acute stroke in previous 48 h | 14 d Heparin v. no heparin | IS, %<br>2.9<br>Death or nonfatal stroke, %<br>11.7<br>12.0 | 0.76 (0.65–0.89)<br>0.97 (0.89–1.05) | No heparin | Decrease in recurrent IS in heparin group offset by increased risk of HS (OR 2.95, 95% CI 2.07–4.21) |
| IST subgroup | Acute stroke in previous 48 h + AF | 14 d (no effect on death/dependency at 6 mo follow-up) High-dose heparin v. low-dose heparin v. no heparin (half of patients in each group received ASA 300 mg) | IS, %<br>2.3<br>Death or nonfatal stroke, %<br>18.8<br>19.4<br>20.7 | 0.56 (0.39–0.82)<br>0.91 (0.76–1.08) | No heparin | Decrease in recurrent IS in heparin group offset by increased risk of HS (OR 4.81, 95% CI 2.12–10.9) |
| TAIST    | Acute stroke in previous 48 h | 10 d (no difference in 6 mo independence between groups) High-dose tinzaparin v. low-dose tinzaparin v. ASA | Stroke, %<br>3.3<br>4.7<br>3.1<br>Death, %<br>3.5<br>5.5<br>3.5 | 1.08 (0.53–2.21)<br>1.58 (0.82–3.04)<br>1.07 (0.55–2.11)<br>1.63 (0.88–3.02) | No difference in main outcome measures | Large increase in early SICH with tinzaparin treatment (OR for high-dose tinzaparin 7.15, 95% CI 1.10–163) |
| EAFT     | AF + recent TIA or stroke | 2.3 yr AC v. ASA v. placebo | Stroke risk, %<br>4<br>10<br>12<br>Major and fatal bleeding, %<br>2.8<br>0.9<br>0.7 | 0.38 (0.23–0.64) | AC | Clear benefit of AC over ASA in preventing recurrent stroke secondary to AF; significant increase in bleeding events for AC compared to ASA (HR 2.8, CI 1.7–4.8) and placebo (HR 3.4, CI 1.9–6.0) |
| SPAF-III  | AF + 1 thromboembolic risk factor | 1.1 yr (stopped early) AC (INR 2–3) v. AC (INR 1.2–1.5) + ASA | Stroke or systemic embolism per yr<br>1.9<br>7.9<br>Disabling stroke per yr<br>1.7<br>5.6 | 0.23 (0.11–0.46)<br>0.30 (0.14–0.63) | AC (INR 2–3) | Rates of major bleeding similar in both groups (2.4% and 2.1%) |
| SPIRIT   | TIA or IS of noncardiac origin in previous 6 mo | 14 mo AC (INR 3.0–4.5) v. ASA 30 mg | Composite of death, stroke, MI, major bleeding, %<br>12.4<br>5.4 | HR 2.3 (1.6–3.5) | ASA | No benefit for high-intensity AC over ASA in noncardioembolic stroke |
| WARSS    | IS of noncardiac origin in previous 30 d | 2 yr AC (INR 1.4–2.8) v. ASA 325 mg | IS or death, %<br>17.8<br>16.0<br>Major bleeding per 100 patient-yr<br>2.2<br>1.5 | 1.13 (0.92–1.38) | No difference | No benefit for low-to mid-intensity AC over ASA in noncardioembolic stroke |

Note: When not provided in the study, unadjusted ORs and 95% CIs were calculated. HS = hemorrhagic stroke, AF = atrial fibrillation, SICH = symptomatic intracranial hemorrhage, AC = anticoagulation, INR = international normalized ratio, HR = hazard ratio, DM = diabetes mellitus, LVH = left ventricular hypertrophy.
whether aggressive anticoagulation or surgical treatment is truly warranted.

**Recurrent stroke of noncardioembolic origin**

Anticoagulation may seem an attractive option for patients with recurrent cerebrovascular ischemia without an identifiable cardiac source in whom antithrombotic options have been exhausted. However, one study demonstrated no difference between ASA and warfarin (target INR 1.4–2.8) in reducing the risk of recurrent noncardioembolic stroke\(^\text{61}\) (Table 2). A similar study also found that anticoagulation (target INR 3.0–4.5) was associated with an increased risk of overall bleeding compared with ASA (OR 2.31).\(^\text{59}\) Although ASA is sufficient prophylaxis as primary prevention,\(^\text{69}\) for patients who have had a previous thrombotic event, anticoagulation greatly reduces the risk of recurrent events, both venous and arterial (hazard ratio [HR] 0.32, 95% CI 0.15–0.7 for INR < 3) as compared with ASA (HR 0.93, 95% CI 0.51–1.68).\(^\text{61}\)

The presence of antiphospholipid antibody is an independent risk factor for first ischemic stroke, occurring in 9.7% of stroke patients versus 4.3% of control subjects in one study (adjusted OR 2.31).\(^\text{59}\) Although ASA is sufficient prophylaxis as primary prevention,\(^\text{69}\) for patients who have had a previous thrombotic event, anticoagulation greatly reduces the risk of recurrent events, both venous and arterial (hazard ratio [HR] 0.32, 95% CI 0.15–0.7 for INR < 3) as compared with ASA (HR 0.93, 95% CI 0.51–1.68).\(^\text{61}\)

**Summary**

Heparin should be avoided in the treatment of acute stroke. Treatment with warfarin for patients with atrial fibrillation without prior TIA or stroke is outlined in Table 3. Warfarin is also indicated as primary stroke prevention for patients with prosthetic heart valves and for recent acute myocardial infarction (< 3 months) with apical hypokinesis or thrombus and as secondary prevention in the presence of antiphospholipid antibody. It may also be indicated for recurrent cryptogenic stroke with PFO.

**Antihypertensive medications**

Observational studies demonstrate the strong positive association of stroke risk with rising blood pressure in patients with or without previous cerebrovascular events.\(^\text{65}\) Each 7.5-mm Hg rise in diastolic blood pressure doubles the risk of stroke,\(^\text{64}\) while isolated systolic hypertension confers an even greater risk, especially among middle-aged men, who have an almost 5-fold risk of stroke.\(^\text{61}\) A meta-analysis of some of the largest primary prevention trials of thiazides and \(\beta\)-blockers, totalling nearly 50 000 patients, demonstrated a 38% relative risk reduction in the rates of primary stroke with a difference of 5–6 mm Hg in diastolic blood pressure over 5 years.\(^\text{64}\) Numerous guidelines have been developed for the treatment of hypertension\(^\text{65–68}\) that emphasize a target blood pressure of less than 140/90 mm Hg and less than 130/85 mm Hg for patients who have had a previous cerebrovascular event and have diabetes or other vascular disease.

The question of which antihypertensive medication should be the first choice remains controversial. Thiazide diuretics, angiotensin-converting-enzyme (ACE) inhibitors, angiotensin receptor blockers and \(\beta\)-blockers have all been studied (Table 4). Although thiazides and ACE inhibitors are both widely accepted as first-line therapy, choosing one over the other remains a contentious issue. While some studies have favoured thiazides\(^\text{64}\) and others ACE inhibitors,\(^\text{72–74}\) others have found no difference\(^\text{72}\) (Table 4). Practically, many patients require more than 1 antihypertensive to achieve normal blood pressure, which makes the need to choose one over the other irrelevant. Indeed, in one study the combination of ACE inhibitors and the diuretic indapamide was shown to be more effective than monotherapy for secondary stroke prevention.\(^\text{77}\) The LIFE study\(^\text{75}\) (Table 4) suggests a role for angiotensin-receptor blockers (ARBs) in primary stroke prevention, demonstrating a 25% reduction in stroke for losartan when compared with atenolol. A substudy\(^\text{76}\) of patients with left ventricular hypertrophy and isolated systolic hypertension demonstrated an even more impressive 40% stroke reduction.

Although restoration of normal blood pressure remains central to preventing strokes, studies of ACE inhibitors or angiotensin-receptor blockers have demonstrated reductions in rates of stroke with very modest reductions in blood pressure.\(^\text{74,78}\) Angiotensin-II is known to increase VCAM-1 expression and the production of inflammatory cytokines that promote atherogenesis\(^\text{79,80}\) (Fig. 1). Therefore, inhibition of angiotensin-II may have protective effects beyond blood pressure control.

**Summary**

Treatment of hypertension significantly reduces the risk of stroke. Both thiazides and ACE inhibitors have been shown to reduce this risk. Although there is controversy in the choice of the first-line medication, many patients require a combination of 2 or more antihypertensive drugs to

---

**Table 3: Treatment of atrial fibrillation in primary stroke prevention**

| Age   | Treatment          |
|-------|--------------------|
| < 65 yr | No risk factors   | ASA |
| 1 or more risk factors† | Warfarin (INR 2–3) |
| 65–75 yr | No risk factors   | ASA or warfarin (INR 2–3) |
| 1 or more risk factors† | Warfarin (INR 2–3) |
| > 75 yr   | Warfarin (INR 2–3) |     |

*Adapted, with permission, from Laupacis et al.*

†Risk factors include prior transient ischemic attack, systemic embolus or stroke, hypertension, left ventricular dysfunction, diabetes mellitus and coronary artery disease.
normalize blood pressure.79 Therefore, thiazides, ACE inhibitors or a combination of both should all be considered as first-line therapy. Additional therapies should depend on the clinical circumstances. Patients intolerant of ACE inhibitors should be treated with an angiotensin-receptor blocker, particularly in the presence of diabetes or left-ventricular hypertrophy for renal protective effects and cardiac afterload reduction respectively. β-Blockers may be preferred in the presence of diabetes, coronary artery disease or congestive heart failure.67

### Lipid-lowering agents

LDL plays an important role in the formation of atherosclerotic plaques and the endothelial inflammatory pathway. Traditionally, the rationale of treating hyperlipidemia was to reduce the amount of substrate available for plaque formation. However, there is increasing evidence that agents used to treat hyperlipidemia, in particular the HMG–CoA reductase inhibitors (statins), also have anti-inflammatory and endothelial protective effects that are independent of lipid lowering and confer protection against vascular events. For example, statins have been shown to reduce levels of C-reactive protein, which results in a decreased risk of coronary events independent of lipid lowering.81,82

Unlike coronary artery disease, there is surprisingly little evidence to support a correlation between elevated serum cholesterol levels and overall cerebrovascular events. Prospective observational cohorts, with 450 000 patients, demonstrated no correlation except among patients under the age of 45.83 This may be in part because a positive association with nonhemorrhagic stroke is offset by an observed inverse relation with intracranial hemorrhage.84,85

Meta-analyses have shown that statins reduce the risk of

| Trial                     | Patients | Follow-up | Intervention                  | Absolute risk | OR (95% CI)       | Superior | Comments                          |
|---------------------------|----------|-----------|--------------------------------|---------------|-------------------|----------|-----------------------------------|
| ALLHAT71                   | n = 33357| 4.9 yr    | Stroke, %                      | Am v. CT      | 0.93 (0.82–1.06)  | None     | 15% greater risk of stroke in LS group and 40% in black population, but mean BP also higher |
| STOP-272                   | n = 6614 | 5 yr      | Stroke per 1000 patient-yr     | Am v. diuretic| 0.90 (0.74–1.08)  | None     | BP lowering similar in all groups (35/16–17 mm Hg). Conventional treatment included β-blocker or thiazides, or both |
| Second Australian National Blood Pressure Study Group73 | n = 6083 | 4.1 yr    | Nonfatal stroke per 1000 patient-yr | HR 0.93 (0.70–1.26) | HR 1.91 (1.04–3.50) | Possibly ACE inhibitors | BP lowering 26/12 mm Hg in both groups. Reduced number of cardiovascular events in ACE inhibitor group, but increase in fatal strokes |
| HOPE74                     | n = 9297 | 4.5 yr    | Total stroke, %                | ACE inhibitors v. placebo | 0.68 (0.56–0.84) | ACE inhibitors | BP lowering 3.8/2.8 mm Hg in ACE inhibitor group and 0.7/1.1 mm Hg in placebo group |
| LIFE75                     | n = 9193 | 4.8 yr    | Total stroke per 1000 patient-yr | Losartan v. atenolol | 0.75 (0.63–0.89) | Losartan | BP lowering similar in both groups: losartan 30/17 mm Hg atenolol 29/17 mm Hg |
| LIFE substudy76            | n = 1326 | 4.7 yr    | Total stroke per 1000 patient-yr | Losartan v. atenolol | 0.60 (0.38–0.92) | Losartan | BP lowering 28/9 mm Hg in both groups |
| PROGRESS77                 | n = 6105 | 3.9 yr    | Total stroke, %                | ACE inhibitors + diuretic v. double placebo | 0.95 (0.77–1.19) | ACE inhibitors + diuretic | BP lowering 5/3 mm Hg in ACE inhibitor group and 12/5 mm Hg in ACE inhibitor + diuretic group |

Note: When not provided in the study, unadjusted ORs and 95% CIs were calculated. HTN = hypertension, CAD = coronary artery disease, AM = amiodipine, CT = chlorthalidone, LS = lisinopril, BP = blood pressure, SBP = systolic blood pressure, DBP = diastolic blood pressure, ACE = angiotensin-converting enzyme, CCB = calcium-channel blocker.
stroke. However, atorvastatin was recently shown to decrease the risk of stroke among patients not traditionally deemed hyperlipidemic (total cholesterol < 6.5 mmol/L) but who had multiple vascular risk factors. Among patients who had previous coronary artery disease, both simvastatin and pravastatin have been shown to decrease the risk of stroke without any increase in the risk of hemorrhagic stroke. The Heart Protection Study (HPS) (Table 5) has now lowered the lipid treatment threshold even further in high-risk groups, demonstrating marked reductions in all vascular events with baseline LDL as low as 2.5 mmol/L, irrespective of age, sex and other treatments.

Patients with low or normal LDL (< 3.6 mmol/L), low high-density lipoprotein (HDL) levels (< 0.81 mmol/L) and coronary artery disease may also benefit from gemfibrozil, a fibrate drug, which has been shown to reduce the risk of stroke by 31% (Table 5). However, the safety and efficacy of gemfibrozil in combination with statins are unclear.

A meta-analysis of nonstatin interventions showed that a treatment strategy to reduce total cholesterol below 6 mmol/L with fibrate drugs, niacin and diet reduced the risk of stroke.

**Summary**

All patients with prior TIA, ischemic stroke or with high risk factors for vascular disease as defined by HPS criteria should be treated with a statin irrespective of their serum cholesterol level. Fibrate drugs may also reduce the risk of stroke; however, the safety and efficacy of the combination of the fibrate and statin drugs are not clear.

**Carotid endarterectomy**

Carotid endarterectomy of a symptomatic severe stenosis of an internal carotid artery remains one of the most effective methods of preventing recurrent stroke, reducing the risk by up to two thirds (Table 6). The national guideline recommends treatment of patients with high-grade stenosis (≥ 70%) and 20 for moderate stenosis (50%–69%).

Endarterectomy for asymptomatic stenosis of the internal carotid artery remains controversial. Although one study demonstrated a 53% relative risk reduction in ipsilateral stroke and death over 5 years, the number of events was small, with a higher NNT and men appeared to benefit considerably more than women. Long-term benefits may also be outweighed by the early risks of excess perioperative stroke or death (relative risk [RR] 6.52, 95% CI 2.66–15.96) and are influenced by the complication rates of individual surgeons. Guidelines suggest that surgery should be considered only for asymptomatic carotid disease if the complication rate is less than 3% and the stenosis is greater than 60%. The age and health of the patient, plaque stability and presence of coexisting cerebral artery disease should also be considered.

### Table 5: Major trials of lipid-lowering agents

| Trial       | Patients | Follow-up | Intervention | Absolute risks | OR (95% CI) | Superior | Comments |
|-------------|----------|-----------|--------------|----------------|-------------|----------|----------|
| WOSCOPS<sup>88</sup> | Men aged 45–64 yr, n = 6595 | 4.9 yr | Pravastatin v. placebo | Stroke, % | – | None | In pravastatin group, TC decreased 20%, LDL decreased 26% |
| ASCOT-LLA<sup>89</sup> | HTN ≥ 3 other vascular risk factors, n = 10 305 | 3.3 yr | Atorvastatin v. placebo | Total stroke per 1000 patient-yr | HR 0.73 (0.56–0.96) | Atorvastatin | In atorvastatin group, TC decreased 19%, LDL decreased 29% |
| 4-S<sup>90</sup> | CAD + TC 5.5–8.0 mmol/L, n = 4 444 | 5.4 yr | Simvastatin v. placebo | Stroke rate, % | 0.63 (0.46–0.88) | Simvastatin | In simvastatin group, TC decreased 25%, LDL decreased 35% |
| PPP CARE + LIPID trials combined<sup>91</sup> | CAD + “average” lipid levels; mean TC CARE 4.8 mmol/L, LIPID 6.1 mmol/L, n = 6 593 | CARE 4.8 yr LIPID 6.1 yr | Pravastatin v. placebo | Strokes per 1000 patient-yr | HR 0.78 (0.65–0.93) | Pravastatin | – |
| HPS<sup>92</sup> | History of vascular disease or DM, n = 20 536 | 5 yr | Simvastatin v. placebo | All stroke, % | 0.75 (0.66–0.85) | Simvastatin | Benefits irrespective of initial cholesterol levels |
| VA-HIT<sup>93</sup> | CAD HDL < 1.03 mmol/L, LDL < 3.6 mmol/L, Trig < 3.39 mmol/L, n = 2 531 | 5.1 yr | Gemfibrozil v. placebo | Total stroke, % | Unadjusted OR 0.76 (0.53–1.07), Adjusted RRR 31% (2%–52%) | Gemfibrozil | In gemfibrozil group, HDL increased 6%, TC decreased 4%, Trig decreased 31% |

Note: When not provided in the study, unadjusted ORs and 95% CIs were calculated. TC = total cholesterol, LDL = low-density lipoprotein, HTN = hypertension, HDL = high-density lipoprotein, Trig = triglycerides, RRR = relative risk reduction.
Summary

Carotid endarterectomy remains the definitive treatment in patients with symptomatic stenosis of the internal carotid artery of 70% or higher and in selected patients with a stenosis of 50%–69%. We do not currently recommend surgery for asymptomatic disease, preferring to treat proven vascular risk factors aggressively with immediate follow-up in the event of any stroke symptoms.

Conclusion

We have presented the current understanding of the pathophysiology of atherosclerosis, the most important cause of stroke and the evidence available for the medical and surgical interventions for the prevention of stroke. Based on the evidence, it is clear that the use of an antiplatelet agent or warfarin and the correction of hypertension and hyperlipidemia all reduce the risk of stroke. In patients with symptomatic and severe internal carotid stenosis, it is also clear that carotid endarterectomy is the treatment of choice for stroke prevention.

The research in stroke prevention is ongoing with the evaluation of new drugs, refinement of knowledge of current medications and the tailoring of treatments for appropriate patient groups. Although beyond the scope of this review, the modification of lifestyle factors such as smoking and obesity remain crucial components to the prevention of stroke. Stroke risk may be reduced by almost 50% with regular exercise alone.

The management of risk factors after stroke in general is not optimal and requires an increase in both the awareness of these risk factors and the appropriate, evidence-based use of existing therapeutic interventions. We have attempted to present the findings of important clinical trials to ascertain these risks and potential benefits, and we believe there is a need for more aggressive monitoring and treatment by both primary care physicians and specialists alike.

This article has been peer reviewed.

From the Stroke Prevention Clinic, University of Alberta Hospital, Mackenzie Health Sciences Centre (O'Rourke, Akhtar, Shuaib), and the Department of Medicine, Royal Alexandra Hospital (Dean), Edmonton, Alta.

Competing interests: None declared for Fintan O'Rourke and Naveed Akhtar. Ashfaq Shuaib has received speaker fees and travel assistance from Sanofi-Synthelabo, Boehringer Ingelheim, Roche and Pfizer. Naeem Dean has received speaker fees from Sanofi-Synthelabo and Servier.

Contributors: Fintan O'Rourke, as the main author, was responsible for the writing, conception, intellectual content and design of the manuscript. Naeem Dean, Naveed Akhtar and Ashfaq Shuaib contributed to the intellectual content and design of the manuscript. All authors critically reviewed and approved the final version of the manuscript.

References

1. Selected leading causes of death by sex. Ottawa: Statistics Canada; 1997.
2. Hodgson C. Prevalence and disabilities of community-living senior who report the effects of stroke. CMAJ 1998;159(6 Suppl):95-14S.
3. American Heart Association. 2002 heart and stroke statistical update. Dallas: The Association; 2001.
4. Moore R, Mao Y, Zhang J, Clarke K. Economic burden of illness in Canada, 1993. Ottawa: Health Canada; 1997. Cat no H21-136/1993E.
5. Johnston SC, Gress DR, Browner WS, Sidney S. Short-term prognosis after emergency department diagnosis of TIA. JAMA 2000;284(22):2981-6.
6. Hankey GJ, Jamrozik K, Broadhurst RJ, Forbes S, Burvill PW, Anderson CS, et al. Long-term risk of first recurrent stroke in the Perth Community Stroke Study. Stroke 1998;29(12):2491-500.
7. Petty GW, Brown RD Jr, Whisnant JP, Sicks JD, O’Fallon WM, Wiebers DO. Ischemic stroke subtypes: a population-based study of functional out-

Table 6: Major trials of carotid endarterectomy

| Trial    | Patients | Follow-up | Intervention | Absolute risk, % | OR (95% CI) | Superior | Comments |
|----------|----------|-----------|--------------|------------------|-------------|----------|----------|
| NASCET<sup>10</sup> n = 649 | 70%–99% symptomatic carotid stenosis | 18 mo | CEA v. medical care | Stroke or death | 15.8 | 0.50 (0.33–0.77) | CEA | Clear early benefits for CEA in severe symptomatic carotid disease |
| NASCET<sup>6</sup> n = 858 | 50%–69% symptomatic carotid stenosis | 5 yr | CEA v. medical care | Stroke or death | 33.2 | 0.67 (0.51–0.90) | CEA | Benefits obtained largely in first 2–3 yr after CEA; no benefits from CEA with stenosis < 50% |
| ECST<sup>6</sup> n = 3024 | TIA or nondisabling stroke in previous 6 mo related to carotid stenosis | CEA 3 yr; Medical care 3.2 yr | CEA v. medical care | Stroke or death at 3 yr for ≥ 80% ICA stenosis | 14.9 | HR 0.78 (CI not provided) p = 0.01 | CEA | 80% stenosis on ECST criteria is equal to 70% stenosis on NASCET criteria |
| ACAS<sup>5</sup> n = 1662 | Asymptomatic carotid stenosis ≥ 60% | 2.7 yr | CEA v. medical care | Ipsilateral stroke and perioperative stroke or death | 5.1 | 0.63 (0.40–0.98) | CEA | CEAs for asymptomatic carotid disease remains controversial |
| CAVATAS<sup>5</sup> n = 504 | Carotid stenosis suitable for CEA or endovascular treatment | CEA 1.98 yr; Endovascular treatment 1.95 yr | Endovascular treatment v. CEA | Death or disabling stroke | 14.3 | 1.03 (0.64–1.64) | None | Higher rates of procedural stroke than those reported in other major trials for CEA |

Note: When not provided in the study, unadjusted ORs and 95% CIs were calculated. CEA = carotid endarterectomy, ICA = internal carotid artery.
come, survival, and recurrence. Stroke 2000;31(3):1062-8.

8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105(9):1135-43.

9. Li H, Cobo MI, Gimbrone MA Jr, Libby P. An atherogenic diet rapidly induces VCAM-1, a cytokine-regulatable mononuclear leukocyte adhesion molecule, in rabbit aortic endothelium. Arterioscler Thromb 1993;13(2):197-204.

10. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, et al. Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998;2(2):275-81.

11. Hansson G, Libby P. The role of the lymphocyte. In: Fuster V, Ross R, Topol E, editors. Atherosclerosis and coronary artery disease. New York: Lippincott-Raven, 1996:1-68.

12. Topper JN, Cai J, Fall D, Gimbrone MA Jr. Identification of vascular endothelial genes differentially responsive to fluid mechanical stimuli: cyclooxygenase-2, manganese superoxide dismutase, and endothelial nitric oxide synthase are selectively up-regulated by steady laminar shear stress. Proc Natl Acad Sci U S A 1996;93(19):10417-22.

13. De Caterina R, Libby P, Peng HB, Thanackal VJ, Rajnishshath TB, Gimbrone MA Jr, et al. Nitric oxide decreases cytokine-induced endothelial activation. Nitric oxide selectively reduces endothelial expression of adhesion molecules and proinflammatory cytokines. J Clin Invest 1995;96(1):60-8.

14. Lee RT, Yamamoto C, Feng Y, Potter-Perrigo S, Briggs WH, Landschulz KT, et al. Mechanical strain induces specific changes in the synthesis and organization of proteoglycans by vascular smooth muscle cells. J Biol Chem 2001;276(17):13847-51.

15. Libby P. Current concepts of the pathogenesis of the acute coronary syndromes. Circulation 2001;104(3):365-72.

16. Libby P, Simon T, Bhatt D. Organisation and thrombosis: the clot thickens. Circulation 2001;103(13):1718-21.

17. Woolard KJ, Phillips DC, Griffiths HR. Direct modulatory effect of C-reactive protein on primary human monocyte adhesion to human endothelial cells. Clin Exp Immunol 2002;130(2):254-62.

18. Pasicer V, Willerson JT, Yeh ET. Direct proinflammatory effect of C-reactive protein on human endothelial cells. Circulation 2000;102(18):2165-8.

19. Zwaal TP, Hornbach V, Torzewski J. C-reactive protein-mediated low density lipoprotein uptake: macrophages: implications for atherosclerosis. Circulation 2001;103(9):1194-7.

20. Saito M, Ishimitsu T, Minami J, Ono H, Ohrui M, Matsuoka H. Relations of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. J Mol Cell Cardiol 1999;31(4):657-68.

21. Saxena R, Lewis S, Berge E, Sandrock PA, Koustitl DJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32(10):2333-7.

22. Barth PM, Lindenstrom E, Boysen G, De Deyn P, Fris P, Leys D, et al. Timzaparin in acute ischemic stroke (TIAST): a randomized aspirin controlled trial. Lancet 2001;358(9283):702-10.

23. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. EAF (European Atrial Fibrillation Trial) Study Group. Lancet 1993;342(8882):1253-62.

24. Adjusted-dose warfarin versus low-intensity, fixed-dose warfarin plus aspirin for high-risk patients with atrial fibrillation: Stroke Prevention in Atrial Fibrillation III randomized clinical trial. Lancet 1996;348(9028):633-8.

25. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. Arch Neurol 1997;42(6):875-80.

26. Almers K, Thompson JL, Lazar MV, Levin B, Sacco RL, Furie KL, et al., for the Warfarin-Aspirin Re recent Stroke Study Group. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001;345(20):1444-51.

27. Risk factors for stroke and efficacy of antiplatelet therapy in atrial fibrillation. Analysis of pooled data from five randomized controlled trials. Arch Intern Med 1994;154(13):1449-57.

28. Hylek EM, Go AS, Chang Y, Jensvold NG, Henaidi LE, Selby J, et al. Efficacy and intensity of oral anticoagulation on stroke severity and mortality in atrial fibrillation. N Engl J Med 2003;349(11):1019-26.

29. Van Gelder IC, Hagens VE, Bokser HA, Kangma JH, Kamp O, Kingma T, et al, Rate Control versus Electrical Cardioversion for Persistent Atrial Fibrillation Study Group. A comparison of rate control and rhythm control in patients with recurrent persistent atrial fibrillation. N Engl J Med 2002;347(23):1834-40.

30. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, et al, Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002;347(23):1825-33.

31. Stein PD, Alpert JS, Bussey HI, Dalen JE, Turpie AG. Antiplatelet therapy in patients with mechanical and biological prosthetic heart valves. Chest 2001;119(6 Suppl):2270-2275.

32. Noulas P, Wolf PA, Kase CS, Kelly-Hayes M, Silbershatz H, Massaro JM, et al. Plasma concentration of C-reactive protein and risk of ischemic stroke and transient ischemic attack: the Framingham study. Stroke 2001;32(11):2757-9.

33. Dicker LW. A metaregression analysis of the dose–response effect of aspirin on stroke. Arch Intern Med 1996;156(19):1329-39.

34. Diener HC, Darius H, Bertrand-Hardy JM, Humphreys M. European Stroke Prevention Study 2. Cardiac safety in the European Stroke Prevention Study 2 (ESPSP2). Int J Clin Pract 2001;55(3):162-3.

35. Varenne O, Zhao F, Mehra MR, Pocock SJ, Tognoni G, Fox KK, and The Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation [published errata in N Engl J Med 2007;357(14):1516, 1716]. N Engl J Med 2001;345:449-502.

36. International Stroke Trial (IST): a randomized trial of aspirin, subcutaneous heparin, both, or neither among 19435 patients with acute ischemic stroke. International Stroke Trial Collaborative Group. Lancet 1997;349(9065):1569-81.

37. Saxena R, Lewis S, Berge E, Sandrock PA, Koustitl DJ. Risk of early death and recurrent stroke and effect of heparin in 3169 patients with acute ischaemic stroke and atrial fibrillation in the International Stroke Trial. Stroke 2001;32(10):2333-7.

38. Rourke et al 2002;105(9):1135-43.
non-cardioembolic stroke patients: effect of medical therapy. J Am Coll Cardiol 2003;42(6):1066-72.

Anticardiolipin antibodies are an independent risk factor for first ischemic stroke. The Antiphospholipid Antibodies in Stroke Study (APASS) Group. Neurology 1993;43(10):2069-73.

Cuadrajo MJ, Khamashta MA. The anti- phospholipid antibody syndrome (Hughes syndrome): therapeutic aspects. Basillaris Best Pract Res Clin Rheumatol 2000;14(1):151-63.

Khamashta MA, Cuadrajo MJ, Mujic F, Taub NA, Hunt BJ, Hughes GR. The management of thrombosis in the antiphospholipid-antibody syndrome. N Engl J Med 1995;332(15):997-7.

Laupacis A, Alberts D, Dunn ML, Jacobson AK, Singer DE. Anti-thrombotic therapy in atrial fibrillation. Chest 1998;114(5 Suppl):S795-99S.

Kannel WB, Wolf PA, Vetter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke. The Framingham study. JAMA 1970;214(2):301-10.

MacMahon S, Petro R, Cutler J, Collins R, Sorlie P, Neaton J, et al. Blood pressure, stroke, and coronary heart disease. Part 1. Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990;335(8692):765-74.

Petrovitch H, Carlb JD, Bloom-Marcus E. Isolated systolic hypertension and risk of stroke in Japanese-American men. Stroke 1995;26(1):25-9.

Collins R, MacMahon S. Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994;50(2):272-98.

McAlister FA, Zarnke KB, Campbell NR, Feldman RD, Levine M, Mahon J, et al, for Canadian Hypertension Recommendations Working Group. The 2001 Canadian Recommendations for the management of hypertension: part two — therapy. Can J Cardiol 2002;18:625-41.

1999 World Health Organization-International Society of Hypertension guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999;17(2):151-83.

Staessen JA, Wang J. Blood-pressure lowering for the secondary prevention of stroke. Lancet 2001;358(9287):1026-7.

Chobanian AV, Bakris GL, Black HR. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003;289(19):2560-72.

Major outcomes in high-risk hypertensive patients randomized to angio- tensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002;288(23):2981-97.

Hansson L, Lindholm LH, Eliks T, Dahlbo L, Larke J, Schersten B, et al. Randomized trial of old and new antihypertensive drugs in elderly patients: cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999;354(9192):1751-6.

Wing LM, Reil CM, Ryan P, Beilin LJ, Brown MA, Jennings GL, et al, Second Australian National Blood Pressure Study Group. A comparison of outcomes with angiotensin-converting-enzyme inhibitors and diuretics for hy- pertension in the elderly. N Engl J Med 2003;348(7):583-92.

Bosch J, Yusuf S, Pogue J, Sleight P, Langoonek R, et al; HOPE Investigators. Heart outcomes prevention evaluation. Use of ramipril in prevention of stroke: double-blind randomized trial. BMJ 2002;324(7339):699-702.

Dahlof B, Devereux RB, Kjeldsen SE. Cardiovascular morbidity and mortality in the Losartan Intervention for Endpoint Reduction in hypertension study (LIFE): a randomised trial against amlodipine. Lancet 2002;359(911):1009-13.

Kjeldsen SE, Dahlbo L, Devereux RB, Julius S, Auper S, Edelmann J, et al; LIFE (Losartan Intervention for Endpoint Reduction) Study Group. Effects of losartan on cardiovascular morbidity and mortality in patients with isolated systolic hypertension and left ventricular hypertrophy: a Losartan interven- tion for Endpoint Reduction (LIFE) substudy. JAMA 2002;288(23):1491-8.

PROGRESS Collaborative Group. Randomized trial of a perindopril-based blood-pressure-lowering regimen among 6,103 individuals with previous stroke or transient ischaemic attack. Lancet 2001;358(9287):1031-41.

Luthel H, Hansson L, Skoog I, Einmadel P, Hofman A, Olsson B, Olofsson B, et al; SCOPE Study Group. The Study on Cognition and Prognosis in the Elderly (SCOPE): principal results of a randomized double-blind intervention trial. J Hypertens 2000;18(11):2085-87.

Kranzhofer R, Schmidt J, Pfeiffer CA, Hadl S, Libby P, Kuhler W. Angi- gensin induces inflammatory activation of human vascular smooth muscle cells. Arterioscl Thromb Vasc Biol 1999;19(7):1623-9.

Funmala PE, Chen XL, Sundell CL, Larsen JB, Hammes CP, Alexander RW, et al. Angiotensin II induces vascular cell adhesion molecule-1 expres- sion in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999;100(11):1223-9.

Ridker PM, Rifai N, Pfeiffer MA, Sachs F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. The Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100(3):230-5.

Correspondence to: Fintan O’Rourke, Dept. of Elderly Care Medicine, Barnet General Hospital, Wellhouse Lane, Barnet, UK EN5 3DJ